Sonova Holding stock (CH0012549785): Citi cuts price target amid market pressures

Sonova Holding AG, the Swiss-based global leader in hearing care solutions, faced analyst pressure on May 13, 2026, when Citi analyst Veronika Dubajova reduced the price target to CHF169, according to StreetInsider as of May 13, 2026. The stock traded at 178.20 CHF on May 12, 2026 on SIX Swiss Exchange, up 1.25% for the session, according to SIX Group as of May 12, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Sonova Holding: core business model

Sonova Holding AG develops, manufactures, and distributes hearing instruments and cochlear implants worldwide through established brands including Phonak and other market-leading portfolios. The company operates as a global medtech specialist focused on innovative hearing care solutions, serving millions of patients across multiple continents. Sonova's business model combines direct distribution, partnerships with audiologists and hearing care professionals, and a portfolio spanning traditional hearing aids to advanced digital and AI-enabled audio devices.

Main revenue and product drivers

The company's core revenue streams derive from hearing instruments, cochlear implants, and related hearing care solutions. In August 2024, Sonova introduced Sphere Infinio, a product featuring dual-chip technology with real-time AI sound processing, demonstrating the company's commitment to innovation in the medtech space. The hearing care market remains a significant growth driver for Sonova, supported by aging demographics in developed markets and increasing awareness of hearing health solutions globally.

Strategic positioning and market context

Sonova has been actively reshaping its portfolio through strategic divestitures. The company is separating from non-core business segments, including the sale of its Consumer Hearing business and the Sennheiser brand, according to market reports as of May 2026. This strategic refocus aims to strengthen the company's core medtech operations and enhance shareholder value by concentrating on high-margin hearing care solutions and professional channels.

Conclusion

Sonova Holding AG remains a significant player in the global hearing care medtech sector, with a diversified product portfolio and strong market presence across Europe and North America. The Citi price target reduction reflects near-term market caution, though the company's strategic repositioning and continued innovation in AI-enabled hearing solutions position it within a growing market segment. US investors with exposure to medtech and healthcare innovation may monitor Sonova's upcoming financial results and strategic execution as key catalysts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.